295 related articles for article (PubMed ID: 25658618)
41. Ipilimumab and its toxicities: a multidisciplinary approach.
Fecher LA; Agarwala SS; Hodi FS; Weber JS
Oncologist; 2013 Jun; 18(6):733-43. PubMed ID: 23774827
[TBL] [Abstract][Full Text] [Related]
42. Ipilimumab: a promising immunotherapy for melanoma.
Thumar JR; Kluger HM
Oncology (Williston Park); 2010 Dec; 24(14):1280-8. PubMed ID: 21294471
[TBL] [Abstract][Full Text] [Related]
43. Organizing pneumonia as a side effect of ipilimumab treatment of melanoma.
Barjaktarevic IZ; Qadir N; Suri A; Santamauro JT; Stover D
Chest; 2013 Mar; 143(3):858-861. PubMed ID: 23460165
[TBL] [Abstract][Full Text] [Related]
44. Concurrent Vogt-Koyanagi-Harada disease and impressive response to immune checkpoint blockade in metastatic melanoma.
Gambichler T; Seifert C; Lehmann M; Lukas C; Scheel C; Susok L
Immunotherapy; 2020 May; 12(7):439-444. PubMed ID: 32308086
[No Abstract] [Full Text] [Related]
45. Update on immunologic therapy with anti-CTLA-4 antibodies in melanoma: identification of clinical and biological response patterns, immune-related adverse events, and their management.
Kaehler KC; Piel S; Livingstone E; Schilling B; Hauschild A; Schadendorf D
Semin Oncol; 2010 Oct; 37(5):485-98. PubMed ID: 21074064
[TBL] [Abstract][Full Text] [Related]
46. Anti-CTLA-4 therapy may have mechanisms similar to those occurring in inherited human CTLA4 haploinsufficiency.
Bakacs T; Mehrishi JN
Immunobiology; 2015 May; 220(5):624-5. PubMed ID: 25638260
[TBL] [Abstract][Full Text] [Related]
47. Pembrolizumab-triggered Uveitis: An Additional Surrogate Marker for Responders in Melanoma Immunotherapy?
Diem S; Keller F; Rüesch R; Maillard SA; Speiser DE; Dummer R; Siano M; Urner-Bloch U; Goldinger SM; Flatz L
J Immunother; 2016; 39(9):379-382. PubMed ID: 27662340
[TBL] [Abstract][Full Text] [Related]
48. VOGT-KOYANAGI-HARADA DISEASE-LIKE UVEITIS IN A PATIENT WITH ADVANCED MELANOMA TREATED BY SEQUENTIAL ADMINISTRATION OF NIVOLUMAB AND DABRAFENIB/TRAMETINIB THERAPY.
Madoe A; Schauwvlieghe PP; Jacob J
Retin Cases Brief Rep; 2023 Sep; 17(5):611-615. PubMed ID: 37643052
[TBL] [Abstract][Full Text] [Related]
49. Vogt-Koyanagi-Harada-like syndrome induced by immune checkpoint inhibitors in a patient with melanoma.
Yoshida S; Shiraishi K; Mito T; Sayama K
Clin Exp Dermatol; 2020 Oct; 45(7):908-911. PubMed ID: 32394515
[No Abstract] [Full Text] [Related]
50. Treatment and side effect management of CTLA-4 antibody therapy in metastatic melanoma.
Kähler KC; Hauschild A
J Dtsch Dermatol Ges; 2011 Apr; 9(4):277-86. PubMed ID: 21083648
[TBL] [Abstract][Full Text] [Related]
51. Febrile neutropenia in a metastatic melanoma patient treated with ipilimumab - case report.
Woźniak S; Mackiewicz-Wysocka M; Krokowicz Ł; Kwinta Ł; Mackiewicz J
Oncol Res Treat; 2015; 38(3):105-8. PubMed ID: 25792081
[TBL] [Abstract][Full Text] [Related]
52. Markers for anti-cytotoxic T-lymphocyte antigen 4 (CTLA-4) therapy in melanoma.
Postow MA; Yuan J; Kitano S; Lesokhin AM; Wolchok JD
Methods Mol Biol; 2014; 1102():83-95. PubMed ID: 24258975
[TBL] [Abstract][Full Text] [Related]
53. Durable Response of Metastatic Squamous Cell Carcinoma of the Skin to Ipilimumab Immunotherapy.
Day F; Kumar M; Fenton L; Gedye C
J Immunother; 2017 Jan; 40(1):36-38. PubMed ID: 27684455
[TBL] [Abstract][Full Text] [Related]
54. Trial watch: ipilimumab success in melanoma provides boost for cancer immunotherapy.
Nat Rev Drug Discov; 2010 Aug; 9(8):584. PubMed ID: 20671754
[No Abstract] [Full Text] [Related]
55. The price of tumor control: an analysis of rare side effects of anti-CTLA-4 therapy in metastatic melanoma from the ipilimumab network.
Voskens CJ; Goldinger SM; Loquai C; Robert C; Kaehler KC; Berking C; Bergmann T; Bockmeyer CL; Eigentler T; Fluck M; Garbe C; Gutzmer R; Grabbe S; Hauschild A; Hein R; Hundorfean G; Justich A; Keller U; Klein C; Mateus C; Mohr P; Paetzold S; Satzger I; Schadendorf D; Schlaeppi M; Schuler G; Schuler-Thurner B; Trefzer U; Ulrich J; Vaubel J; von Moos R; Weder P; Wilhelm T; Göppner D; Dummer R; Heinzerling LM
PLoS One; 2013; 8(1):e53745. PubMed ID: 23341990
[TBL] [Abstract][Full Text] [Related]
56. CTLA-4 blockade with monoclonal antibodies in patients with metastatic cancer: surgical issues.
Phan GQ; Weber JS; Sondak VK
Ann Surg Oncol; 2008 Nov; 15(11):3014-21. PubMed ID: 18716842
[TBL] [Abstract][Full Text] [Related]
57. [Vogt-Koyanagi-Harada-like uveitis under immune checkpoint inhibitor treatment for metastasized malignant melanoma].
Mihailovic N; Dyballa J; Herz S; Fluck M; Alnawaiseh M; Merté RL; Eter N
Ophthalmologe; 2020 May; 117(5):467-471. PubMed ID: 31489479
[TBL] [Abstract][Full Text] [Related]
58. Ipilimumab-Induced Granulomatous Disease Occurring Simultaneously With Disease Progression in a Patient With Metastatic Melanoma.
Toumeh A; Sakhi R; Shah S; Arudra SK; De Las Casas LE; Skeel RT
Am J Ther; 2016; 23(4):e1068-71. PubMed ID: 25933140
[TBL] [Abstract][Full Text] [Related]
59. Hypophysitis induced by monoclonal antibodies to cytotoxic T lymphocyte antigen 4: challenges from a new cause of a rare disease.
Torino F; Barnabei A; De Vecchis L; Salvatori R; Corsello SM
Oncologist; 2012; 17(4):525-35. PubMed ID: 22477725
[TBL] [Abstract][Full Text] [Related]
60. Ipilimumab induces simultaneous regression of melanocytic naevi and melanoma metastases.
Libon F; Arrese JE; Rorive A; Nikkels AF
Clin Exp Dermatol; 2013 Apr; 38(3):276-9. PubMed ID: 23020081
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
